EQX vs JHX

Equinox Gold presents a stark contrast between valuation and fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the stock is attractively valued with a Forward P/E of 7.91 and a strong analyst target of $23.00, the deterministic health metrics indicate significant operational instability. Recent price performance has been exceptional over the last year, but a 0/100 technical trend and a massive -83.33% Q/Q revenue decline suggest a looming correction or operational pivot. The investment profile is currently speculative, relying on gold price tailwinds rather than internal financial strength.

JHX presents a stark contrast between deterministic value and growth expectations, with a Piotroski F-Score of 4/9 indicating stable but mediocre financial health and a Graham Number of $7.72 suggesting the stock is significantly overvalued. While revenue growth is robust at 30.10%, earnings have collapsed by 64.10% YoY, leading to an unsustainable trailing P/E of 90.79. The market is currently pricing in a massive recovery, as evidenced by the Forward P/E of 17.45 and a PEG ratio of 0.97. Despite strong analyst buy recommendations, the technical trend is bearish and the intrinsic value is severely disconnected from the current price.